Fig. S7.

Paclitaxel increases expression of xCT, GCLM, and pluripotency factors in vivo. (A and B) MDA-MB-231 subclones (NTC, xCT, or GCLM knockdown) were implanted into the mammary fat pad of female severe combined immunodeficiency (SCID) mice. When tumor volume reached 200 mm³ (day 0), mice were grouped randomly and treated with saline or 10 mg/kg paclitaxel (Pac) on days 0, 5, and 10. Tumors were harvested on day 13. Total RNA was isolated, and RT-qPCR was performed (A). Tissue protein lysates were prepared from tumors, and immunoblot assays were performed and quantified (B) (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC Pac (-); ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. NTC Pac (+).